Das könnte Sie auch interessieren:

Gefährliche Wachstumsschwäche Deutschlands durch Lohnzuwächse und Energiekosten

Brüssel (ots) - Besorgt reagierte der Europaabgeordnete Bernd Lucke (Liberal-Konservative Reformer) auf die ...

Mit Spaß gegen überflüssige Kilos und Jojo-Effekt: Fünf einfache Regeln vom Profi

Lübeck (ots) - Abnehmen ist nicht nur beliebt auf der Liste der guten Vorsätze für das neue Jahr, sondern ...

Die zehn größten Fehler beim Employer Branding

Hamburg (ots) - Die Alleinstellungsmerkmale des Unternehmens nicht kennen, die Bedürfnisse der bestehenden und ...

11.05.2017 – 13:51


Accuray: New Data Presented at ESTRO 36 Reinforce Unmatched Versatility and Precision of the CyberKnife® System

Sunnyvale, California (ots/PRNewswire)

Studies Show the System Provides Excellent Outcomes Throughout the Cancer Treatment Journey, from Primary Cases to Recurrence and Metastatic Disease

Accuray Incorporated (NASDAQ: ARAY) announced today that studies on the clinical use of the leading-edge CyberKnife® System continue to demonstrate its benefits across a wide range of cancer indications and stages in the cancer treatment journey. More than 50 studies were presented during poster and oral sessions at the 36th Annual European Society for Radiotherapy & Oncology (ESTRO) Meeting in Vienna, Austria, May 5 - 9, 2017. Some of the studies presented show long-term efficacy and safety with median follow-up exceeding five years.

(Logo: http://photos.prnewswire.com/prnh/20151126/291246LOGO )

(Photo: http://mma.prnewswire.com/media/510538/Accuray_CyberKnife_Treatment_Delivery_System.jpg )

CyberKnife stereotactic body radiation therapy (SBRT) is used worldwide for effective management of prostate cancer

- Safety, efficacy, and quality of life (QOL) outcomes were reported 
  for 309 patients with low- or intermediate-risk prostate cancer 
  receiving SBRT administered with the CyberKnife System. The study 
  showed cancer control was excellent in both risk groups with 97% of
  patients free from recurrence at five years. Transient decreases in
  bowel and urinary QOL were observed, but returned to baseline. 
  Twenty-one U.S. hospitals participated in this prospective study 
  including Swedish Cancer Institute in Seattle, Washington and Beth 
  Israel Deaconess Medical Center in Boston, Massachusetts.
- A study evaluated the long-term results of CyberKnife prostate SBRT
  delivered either on consecutive days or every other day. The 
  treatment was well-tolerated with high rates of five-year 
  biochemical relapse free survival (BRFS). Low rates of toxicity 
  were unaffected by the treatment schedule. The research was 
  conducted at the Hacettepe University in Ankara, Turkey.
- Long-term results of another study conducted on 329 patients with 
  low- and intermediate-risk prostate cancer revealed that extreme 
  hypofractionated radiotherapy delivered with the CyberKnife System 
  is well tolerated and safe with comparable late toxicity as other 
  treatment modalities. Clinicians of the Erasmus MC Cancer 
  Institute, in Rotterdam (The Netherlands) conducted the study. 

The CyberKnife System provides benefits for primary cases, recurrent and metastatic diseases

Recurrent Disease

- Although re-irradiation of recurrent diseases can be challenging in
  clinical practice, four European studies confirmed its feasibility 
  in prostate and rectal cancer, as well as in recurrent high grade 
  gliomas. These studies concluded that re-irradiation with the 
  CyberKnife System is well-tolerated and effective in controlling 
  local recurring disease.
- A study of CyberKnife SBRT for oligorecurrent liver disease showed 
  treatment was well-tolerated and resulted in favorable survival 
  data. Clinicians at three European hospitals conducted the 
- A study evaluated the efficacy and toxicity of single fraction SBRT
  for isolated nodal failure in prostate cancer patients, after 
  primary surgical or radiation treatment. Treatment with the 
  CyberKnife System provided excellent tolerability and promising 
  biochemical control at 13 months' follow-up. Research was conducted
  at three Italian hospitals. 

Metastatic Disease

- A study of patients with solitary extracranial metastases from 
  gynecologic malignancies demonstrated that SBRT delivered with the 
  CyberKnife® System is well-tolerated and highly effective. An 
  excellent 5-year local control of 93.7% was achieved in patients 
  with classical ovarian and uterine primary tumors. Research was 
  conducted at Georgetown University Hospital in Washington, DC.
- Another study evaluated 206 patients with 326 inoperable pulmonary 
  oligometastases, from colorectal tumors, lung cancers, melanoma, 
  sarcoma, breast carcinoma, and from other sites, treated with SBRT.
  This long-term follow-up study showed good local control (83% at 
  2-years and 73% at 5-years) and overall survival (2, 3, and 5-year 
  OS rates were 63%, 47% and 30%, respectively), as well as low rates
  of serious toxicity. Research was conducted at Erasmus MC-Daniel 
  den Hoed Cancer Center in Rotterdam (The Netherlands). 

Technical innovations improve the delivery of radiation therapy

- New studies reinforce previous data demonstrating intracranial and 
  extracranial treatments delivered using the CyberKnife System 
  InCise(TM) Multileaf Collimator result in comparable target 
  coverage and organ-at-risk sparing to the Iris(TM) Collimator, 
  while significantly reducing treatment times (15% to 47% reduction 
  compared to Iris plans depending on tumor type). Research was 
  conducted at six European hospitals.
- The first study to use three-dimensional performance analysis of 
  the Synchrony® Respiratory Tracking System found it successfully 
  tracks lung tumors regardless of the amplitude of movement. 
  Research was conducted at Hacettepe University in Ankara, Turkey. 

The CyberKnife System was designed to deliver treatment beams of different size and shape from hundreds of non-coplanar, isocentric or non-isocentric angles around the patient, enabling the clinician to deliver high-quality treatment plans with extreme precision, sparing surrounding healthy tissue and structures. The system's tracking capabilities eliminate the need for gating techniques and restrictive head frames, providing greater comfort for the patient.

"I am proud to see that the unique capabilities of our radiation therapy delivery systems are enabling clinicians to develop innovative approaches for delivering radiation treatments which make a real difference in their patients' lives," said Fabienne Hirigoyenberry, VP Global Medical and Scientific Affairs of Accuray. "Since 1994 when the first patient was treated with the CyberKnife System, it has set the bar for delivering precise radiation treatments while avoiding healthy tissue. The data presented at ESTRO 36 reinforce the system's benefits and show it is increasingly being used to treat a wide range of cancer cases."

About Accuray

Accuray Incorporated (NASDAQ: ARAY) is a radiation oncology company that develops, manufactures, and sells precise, innovative tumor treatment solutions that set the standard of care with the aim of helping patients live longer, better lives. The company's leading-edge technologies deliver the full range of radiation therapy and radiosurgery treatments. For more information, please visit http://www.accuray.com .

Safe Harbor Statement

Statements made in this press release that are not statements of historical fact are forward-looking statements and are subject to the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements in this press release relate, but are not limited, to clinical applications, clinical results, patient outcomes and Accuray's leadership position in radiation oncology innovation and technologies. Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from expectations, including but not limited to the risks detailed from time to time under the heading "Risk Factors" in the company's report on Form 10-K, filed on August 24, 2016, the company's reports on Form 10-Q, filed on November 1, 2016, February 3, 2017, and May 5, 2017, and as updated periodically with the company's other filings with the SEC.

Forward-looking statements speak only as of the date the statements are made and are based on information available to Accuray at the time those statements are made and/or management's good faith belief as of that time with respect to future events. The company assumes no obligation to update forward-looking statements to reflect actual performance or results, changes in assumptions or changes in other factors affecting forward-looking information, except to the extent required by applicable securities laws. Accordingly, investors should not put undue reliance on any forward-looking statements.


E-Mail: snakarat@accuray.com

Liliana Silva Fernandes
Elan Edelman
Tel: +33-1-86-21-50-37
E-Mail: liliana.silvafernandes@elanedelman.com

Original-Content von: Accuray, übermittelt durch news aktuell

Alle Meldungen
Abonnieren Sie alle Meldungen von Accuray
  • Druckversion
  • PDF-Version

Orte in dieser Meldung

Themen in dieser Meldung